Document Detail


Leukaemia inhibitory factor (LIF) is immunohistochemically expressed in normal, hyperplastic and malignant endometrial tissue.
MedLine Citation:
PMID:  15596282     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Leukaemia inhibitory factor (LIF) is a pleiotrophic cytokine, which might play an important role in human reproduction and endocrine-responsive tumours. Therefore, the aim of this study was to determine the frequency and tissue distribution of LIF in normal, hyperplastic and malignant endometrium. STUDY DESIGN: Paraffin-fixed endometrial tissue was obtained from normal premenopausal women (n = 15), endometrial hyperplasia (n = 20), endometroid adenocarcinoma (n = 32) and endometrial polyps (n = 9). The LIF expression was demonstrated by immunohistochemical means and evaluated with a semi-quantitative immunoreactive score. The Mann-Whitney U-test was used for statistical evaluation. RESULTS: The lowest expression of LIF was observed in endometrial adenocarcinomas compared to all groups, while endometrial polyps expressed the highest LIF immunostaining. The expression in normal human glandular cells was significantly higher during the late secretory phase than in the proliferative phase. The highest expression of LIF was observed in endometrial polyps. Simple hyperplasia showed a significantly higher LIF expression than proliferative endometrium and adenocarcinoma. Adenomatous hyperplasia (AH) grade I-III had a significantly higher LIF expression than adenocarcinoma. The lowest expression of LIF was observed in adenocarcinoma, being statistically significant compared to all groups. CONCLUSION: LIF was immunohistochemically demonstrated in normal, hyperplastic and malignant endometrial tissue, suggesting a widespread but complex role for LIF in hyperplastic and malignant endometrial growth regulation. AH I-III also expressed LIF with statistically higher immunostaining than adenocarcinoma. Since AH III can be considered as a precursor of endometrial cancer, LIF could be a marker of cell transformation.
Authors:
Ioannis Mylonas; Josef Makovitzky; Naim Shabani; Dagmar-Ulrike Richter; Christina Kuhn; Udo Jeschke; Volker Briese; Klaus Friese
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of obstetrics, gynecology, and reproductive biology     Volume:  118     ISSN:  0301-2115     ISO Abbreviation:  Eur. J. Obstet. Gynecol. Reprod. Biol.     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2004-12-14     Completed Date:  2005-04-28     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375672     Medline TA:  Eur J Obstet Gynecol Reprod Biol     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  101-8     Citation Subset:  IM    
Affiliation:
First Department of Obstetrics and Gynaecology, Ludwig-Maximilians-University Munich, Maistrasse 11, 80337 Munich, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / chemistry
Endometrial Hyperplasia / metabolism*
Endometrial Neoplasms / chemistry*
Endometrium / chemistry*
Female
Humans
Immunohistochemistry*
Interleukin-6 / analysis*
Leukemia Inhibitory Factor
Polyps / chemistry
Premenopause
Chemical
Reg. No./Substance:
0/Interleukin-6; 0/LIF protein, human; 0/Leukemia Inhibitory Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Influence of the type of anesthesia and hydrodissection on the complication rate after tension-free ...
Next Document:  A remarkable case in the history of obstetrical surgery: a laparotomy performed by the Dutch surgeon...